Category Archives: Pelage Pharmaceuticals

Pelage Pharmaceuticals Raises $16.75 million and Phase 2 Trials to Begin in 2024

Pelage Pharmaceuticals
Pelage Pharmaceuticals Logo.

I previously wrote about Pelage Pharmaceuticals in my 2019 post  related to the research of its President and co-founder Dr. William Lowry. The other co-founders are Dr. Heather Christofk and Michael Jung. I also covered the findings of Dr. Lowry and Dr. Christofk’s UCLA team in a 2017 post.

These UCLA researchers discovered two topical compounds (RCGD423) and (UK5099) that regrew hair in mice via different mechanisms. Both drugs involve an increase in lactate production. This in turn activates hair follicle stem cells and leads to increased and quicker hair growth.

Dr. Lowry’s patent can be found here. Patent and technology rights to both topical drugs have been exclusively licensed to Pelage Pharmaceuticals by UCLA.

Pelage Pharmaceuticals Raises $16.75 Million and Phase 2 Trials to Begin in 2024

February 27. 2024

Great new update (h/t “YoYo”). Pelage Pharmaceuticals has raised $16.75 million in Series A Financing. More importantly, they will begin Phase 2 Clinical Trials for PP405 in mid-2024.

Phase I clinical data met primary safety endpoints. And they confirm that their was statistically significant stem cell activation in hair follicles after just one week of treatment with PP405.

Per CEO Daniel Gil, Ph.D.:

“Our scientific co-founders have uncovered a unique biological mechanism with the potential to reactivate hair growth in people with alopecia.”

The company will present translational data at the American Academy of Dermatology meeting in March 2024.

February 17, 2024

Earlier today, reader “Ben” made an very interesting discovery on Pelage Pharmaceuticals’ website. The following sentence at the bottom:

“Early Phase I clinical data shows statistically significant stem cell activation in the hair follicles after one week of treatment with PP405.”

This is super news. So their trials have started. I wonder if PP405 is RCGD423 or UK5099? Their website homepage describes PP405 as:

“A novel, non-invasive, topical small molecule drug platform that activates stem cells in the hair follicles directly to stimulate robust hair growth. By targeting an intrinsic metabolic switch in hair follicles, Pelage’s platform is suitable for all genders, skin types, and hair types.”

In other recent news, Pelage appointed Dr. Qing Yu Christina Weng as Chief Medical Officer.

RCGD423

RCGD423 activates the JAK-STAT signaling pathway, which in turn leads to an increase in lactate production. This extra lactate activates hair follicle stem cells and results in quicker hair growth.

UK5099

UK5099, blocks pyruvate (a glucose metabolite) from entering cell mitochondria. This also results in an increase in lactate production in the hair follicle stem cells, and therefore accelerates hair growth.

Lowry and Lowe

In 2017, I covered some important groundbreaking hair loss research from UCLA, led by scientists William Lowry and Heather Christofk.

These researchers discovered two topical compounds (RCGD423) and (UK5099) to regrow hair. Both drugs, via different mechanisms, increase the production of lactate. This in turn activates hair follicle stem cells and leads to increased and quicker hair growth. Dr. Lowry’s patent is here. Note that RCGD423, activates the JAK-STAT signaling pathway.

Dr. Lowry, Pelage Pharmaceuticals and UCLA

Update: January 2023 — Pelage Pharmaceuticals’ new site is live.

Earlier today, reader “PinotQ” posted an important update on progress regarding these compounds’ further development. The compounds and technology have been exclusively licensed by UCLA to Pelage Pharmaceuticals, a startup company founded by Dr. Christofk, Dr. Lowry and Dr. Michael Jung.

Moreover, 100 percent of the shares in Pelage will be purchased by Allergan (Ireland) per an agreement. I have covered pharmaceutical giant Allergan many times on this blog in the past, and they are heavily invested in various new hair growth product technologies.

Rob Lowe has Taken Finasteride for 30 Years. Via his veins.

Rob Lowe Hair Finasteride
Rob Lowe Thick Hair Due to Finasteride?

Actor Rob Lowe has been in the news this week after insulting Prince Williams’ hair loss. Mr. Lowe is 55 years old, and claims that at the first sign of hair loss 30 years ago, he stared taking a hair loss drug. Per the quote below, he took it intravenously via his veins! I assume he means finasteride injections.

Rob Lowe quote:

“The first glimmer that a single hair of mine was going to fall out, I was having that stuff mainlined into my (expletive) veins. And that’s what I did for the next 30 years.”

Prince William Hair Loss
Prince William Balding.

Almost everyone thinks that this drug that Rob Lowe took (and is maybe still taking) is Finasteride, usually given in the form of a pill. Donald Trump takes the same drug for his hair loss.

Dutasteride (Avodart) was not available 30 years ago (the younger Ashton Kutcher got lucky). I am not sure if it is a good idea to get Finasteride delivered through your veins, although Mr. Lowe has to this day maintained a very good head of hair and seems healthy.